SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.

SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024 SPR Therapeutics and the SPRINT PNS System will be featured prominently at the North American Neuromodulation Society Annual Meeting with 11 abstracts.

New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023 Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain

SPR Therapeutics Named a Top Workplace for Second Consecutive Year - Company maintains focus on employee engagement and success while experiencing dynamic growth - CLEVELAND, June 25, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics has been selected as a Top...

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022 CLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets...